IceCure Medical (NASDAQ:ICCM) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

IceCure Medical (NASDAQ:ICCM) announced its quarterly earnings data on Thursday. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01), Zacks reports. The firm had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.07 million. IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%.

IceCure Medical Stock Performance

Shares of NASDAQ ICCM traded down $0.03 during mid-day trading on Friday, hitting $1.08. The company had a trading volume of 50,136 shares, compared to its average volume of 519,411. The company has a current ratio of 2.67, a quick ratio of 2.27 and a debt-to-equity ratio of 0.02. IceCure Medical has a 1 year low of $0.48 and a 1 year high of $1.66. The company has a market capitalization of $59.94 million, a price-to-earnings ratio of -3.72 and a beta of 0.37. The stock’s 50-day moving average price is $1.32 and its 200-day moving average price is $0.98.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.50 target price on shares of IceCure Medical in a research note on Friday.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.